Related Experiment Video
Updated: Jul 16, 2026

Ultrasonographic Evaluation of Salivary Glands for Sjogren's Syndrome: Diagnostic and Monitoring Insights
Published on: October 13, 2023
Lamivudine is not effective in primary Sjögren's syndrome
B Gescuk1, A J Wu, J P Whitcher
1Clinical Trials Center, Division of Rheumatology, University of California, San Francisco, 533 Parnassus Avenue Box 0633 Room U383, San Francisco, CA 94143-0633, USA.
Background:
Retroviral infection has been implicated in the pathogenesis of primary Sjögren's syndrome.
Objective:
To examine the efficacy of the reverse transcriptase inhibitor lamivudine in patients with this syndrome.
Methods:
16 patients with primary Sjögren's syndrome were randomised to receive either lamivudine 150 mg twice daily or placebo for three months. Measures of lacrimal and salivary function, including minor salivary gland biopsies, were obtained before and after treatment.
Results:
Treatment with lamivudine did not result in significant improvement in the primary outcome measure of unstimulated whole salivary flow or other secondary measures, including minor salivary gland biopsy focus scores.
Conclusion:
Lamivudine is not effective in patients with primary Sjögren's syndrome, suggesting either that a retroviral aetiology is not present or that it may be important only in early disease.
More Related Videos
Related Concept Videos
Subviral Agents
Cytomegalovirus Disease
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly

